KLF6 in Nonalcoholic Fatty Liver Disease: Role of Fibrogenesis and Carcinogenesis

Gastroenterology

Volumn 135, Issue 1, 2008, Pages 309-312

  Watanabe, Kiyotaka ^a   Ohnishi, Shin ^b   Manabe, Ichiro ^b   Nagai, Ryozo ^b   Kadowaki, Takashi ^b  

^a NATIONAL CANCER CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 6;

EDITORIAL; HETEROZYGOSITY LOSS; HUMAN; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STELLATE CELL;

EID: 46049102377     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.06.014     Document Type: Editorial

References (34)

1. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
2. Chalasani N., Wilson L., Kleiner D.E., et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 48 (2008) 829-834
3. Marchesini G., Brizi M., Morselli Labate A.M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 (1999) 450-455
4. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
5. Schaffler A., Scholmerich J., and Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 273-280
6. Bugianesi E., McCullough A.J., and Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005) 987-1000
7. Musso G., Gambino R., De Michieli F., et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology 47 (2008) 1167-1177
8. Kadowaki T., Yamauchi T., Kubota N., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 (2006) 1784-1792
9. Tsochatzis E., Papatheodoridis G.V., and Archimandritis A.J. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 101 (2006) 2629-2640
10. Kaser S., Moschen A., Cayon A., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 (2005) 117-121
11. Winau F., Hegasy G., Weiskirchen R., et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 26 (2007) 117-129
12. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88 (2008) 125-172
13. Starkel P., Sempoux C., Leclercq I., et al. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 39 (2003) 538-546
14. Adachi M., and Brenner D.A. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 47 (2008) 677-685
15. Caligiuri A., Bertolani C., Guerra C.T., et al. Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology 47 (2008) 668-676
16. Hellerbrand C., Jobin C., Iimuro Y., et al. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology 27 (1998) 1285-1295
17. Oakley F., Meso M., Iredale J.P., et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 128 (2005) 108-120
18. Wandzioch E., Kolterud A., Jacobsson M., et al. Lhx2-/- mice develop liver fibrosis. Proc Natl Acad Sci U S A 101 (2004) 16549-16554
19. Shindo T., Manabe I., Fukushima Y., et al. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 8 (2002) 856-863
20. Suzuki T., Aizawa K., Matsumura T., et al. Vascular implications of the Kruppel-like family of transcription factors. Arterioscler Thromb Vasc Biol 25 (2005) 1135-1141
21. Ratziu V., Lalazar A., Wong L., et al. Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. Proc Natl Acad Sci U S A 95 (1998) 9500-9505
22. Kojima S., Hayashi S., Shimokado K., et al. Transcriptional activation of urokinase by the Kruppel-like factor Zf9/COPEB activates latent TGF-beta1 in vascular endothelial cells. Blood 95 (2000) 1309-1316
23. Botella L.M., Sanchez Elsner T., Sanz Rodriguez F., et al. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 100 (2002) 4001-4010
24. Kim Y., Ratziu V., Choi S.G., et al. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem 273 (1998) 33750-33758
25. Kremer Tal S., Narla G., Chen Y., et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 46 (2007) 645-654
26. Narla G., Kremer Tal S., Matsumoto N., et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 26 (2007) 4428-4434
27. Teixeira M.S., Camacho Vanegas O., Fernandez Y., et al. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. Intl J Cancer 121 (2007) 1976-1983
28. Camacho Vanegas O., Narla G., Teixeira M.S., et al. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Intl J Cancer 121 (2007) 1390-1395
29. DiFeo A., Feld L., Rodriguez E., et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res 68 (2008) 965-970
30. DiFeo A., Narla G., Hirshfeld J., et al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 12 (2006) 3730-3739
31. Narla G., Difeo A., Reeves H.L., et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 65 (2005) 1213-1222
32. Narla G., DiFeo A., Yao S., et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 65 (2005) 5761-5768
33. Miele L., Beale G., Patman G., et al. The Kruppel like factor 6 (KLF6) genotype is associated with fibrosis in non-alcoholic fatty liver disease (NAFLD). Gastroenterology 134 (2008) 000-000
34. Li D., Yea S., Li S., et al. Kruppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem 280 (2005) 26941-26952